{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:04:01Z","timestamp":1790795041081,"version":"4.1.0"},"reference-count":36,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,11,1]]},"DOI":"10.2169\/internalmedicine.7134-21","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T18:07:02Z","timestamp":1620929222000},"page":"3391-3399","source":"Crossref","is-referenced-by-count":23,"title":["Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease"],"prefix":"10.2169","volume":"60","author":[{"given":"Noriko","family":"Nishimiya","sequence":"first","affiliation":[{"name":"Department of Radiology, Yokohama City University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Tajima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Imajo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kameda","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiko","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Togashi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Aoki","sequence":"additional","affiliation":[{"name":"Internal Medicine, Kanagawa Dental University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomio","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Radiology, Yokohama City University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Utsunomiya","sequence":"additional","affiliation":[{"name":"Department of Radiology, Yokohama City University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Terauchi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Anstee QM, McPherson S, Day CP. How big a problem is non-alcoholic fatty liver disease? BMJ 343: d3897, 2011.","DOI":"10.1136\/bmj.d3897"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD\/NASH based on the EASL 2009 special conference. J Hepatol 53: 372-384, 2010.","DOI":"10.1016\/j.jhep.2010.04.008"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 98: 483-495, 2013.","DOI":"10.1210\/jc.2012-3093"},{"key":"4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","volume":"129","author":"LA Adams","year":"2005","unstructured":"4. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129: 113-121, 2005.","journal-title":"Gastroenterology","ISSN":"https:\/\/id.crossref.org\/issn\/0016-5085","issn-type":"print"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140: 124-131, 2011.","DOI":"10.1053\/j.gastro.2010.09.038"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117-2128, 2015.","DOI":"10.1056\/NEJMoa1504720"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644-657, 2017.","DOI":"10.1056\/NEJMoa1611925"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380: 347-357, 2019.","DOI":"10.1056\/NEJMoa1812389"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Akuta N, Kawamura Y, Watanabe C, et al. Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus. Hepatol Res 49: 531-539, 2019.","DOI":"10.1111\/hepr.13304"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Akuta N, Watanabe C, Kawamura Y, et al. Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies. Hepatol Commun 1: 46-52, 2017.","DOI":"10.1002\/hep4.1019"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ohta A, Kato H, Ishii S, et al. Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes. Expert Opin Pharmacother 18: 1433-1438, 2017.","DOI":"10.1080\/14656566.2017.1363888"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Dixon JB, Bhathal PS, Hughes NR, O&apos;Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology (Baltimore, Md) 39: 1647-1654, 2004.","DOI":"10.1002\/hep.20251"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65: 1190-1195, 2016.","DOI":"10.2337\/db15-1356"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Watanabe S, Hashimoto E, Ikejima K, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. J Gastroenterol 50: 364-377, 2015.","DOI":"10.1007\/s00535-015-1050-7"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.","DOI":"10.1007\/BF00280883"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992, 2009.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Idilman IS, Keskin O, Celik A, et al. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease. Acta Radiol 57: 271-278, 2016.","DOI":"10.1177\/0284185115580488"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Lee SS, Lee Y, Kim N, et al. Hepatic fat quantification using chemical shift MRI and MR spectroscopy in the presence of hepatic iron deposition: validation in phantoms and in patients with chronic liver disease. J Magn Reson Imaging 33: 1390-1398, 2011.","DOI":"10.1002\/jmri.22583"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Shimizu K, Namimoto T, Nakagawa M, et al. Hepatic fat quantification using automated six-point Dixon: comparison with conventional chemical shift based sequences and computed tomography. Clin Imaging 45: 111-117, 2017.","DOI":"10.1016\/j.clinimag.2017.06.006"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 150: 626-637.e627, 2016.","DOI":"10.1053\/j.gastro.2015.11.048"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Tomeno W, Yoneda M, Imajo K, et al. Evaluation of the liver fibrosis index calculated by using real-time tissue elastography for the non-invasive assessment of liver fibrosis in chronic liver diseases. Hepatol Res 43: 735-742, 2013.","DOI":"10.1111\/hepr.12023"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sumida Y, Yoneda M, Hyogo H, et al. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 46: 257-268, 2011.","DOI":"10.1007\/s00535-010-0305-6"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Loomba R, Wolfson T, Ang B, et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology (Baltimore, Md) 60: 1920-1928, 2014.","DOI":"10.1002\/hep.27362"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Baracos V, Kazemi-Bajestani SM. Clinical outcomes related to muscle mass in humans with cancer and catabolic illnesses. Int J Biochem Cell Biol 45: 2302-2308, 2013.","DOI":"10.1016\/j.biocel.2013.06.016"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9: 629-635, 2008.","DOI":"10.1016\/S1470-2045(08)70153-0"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) 97: 2333-2338, 2004.","DOI":"10.1152\/japplphysiol.00744.2004"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The N Engl J Med 355: 2297-2307, 2006.","DOI":"10.1056\/NEJMoa060326"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Xing B, Zhao Y, Dong B, Zhou Y, Lv W, Zhao W. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. J Diabetes Investig 11: 1238-1247, 2020.","DOI":"10.1111\/jdi.13237"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Sattar N, Fitchett D, Hantel S, George JT, Zinman B. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME<sup>\u00ae<\/sup> trial. Diabetologia 61: 2155-2163, 2018.","DOI":"10.1007\/s00125-018-4702-3"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Komiya C, Tsuchiya K, Shiba K, et al. Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PloS One 11: e0151511, 2016.","DOI":"10.1371\/journal.pone.0151511"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Koike Y, Shirabe SI, Maeda H, et al. Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 149: 140-146, 2019.","DOI":"10.1016\/j.diabres.2019.01.029"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Yamashita H, Takenoshita M, Sakurai M, et al. A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc Natl Acad Sci U S A 98: 9116-9121, 2001.","DOI":"10.1073\/pnas.161284298"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Ferr\u00e9 P, Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 12 (Suppl 2): 83-92, 2010.","DOI":"10.1111\/j.1463-1326.2010.01275.x"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Liu G, Li Y, Hu P, Cheng D, Shi H. The combined effects of serum lipids, BMI, and fatty liver on 18F-FDG uptake in the liver in a large population from China: an 18F-FDG-PET\/CT study. Nucl Med Commun 36: 709-716, 2015.","DOI":"10.1097\/MNM.0000000000000301"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Kamimura K, Nagamachi S, Wakamatsu H, et al. Associations between liver (18) F fluoro-2-deoxy-D-glucose accumulation and various clinical parameters in a Japanese population: influence of the metabolic syndrome. Ann Nucl Med 24: 157-161, 2010.","DOI":"10.1007\/s12149-009-0338-1"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes, obesity &amp; metabolism 16: 1087-1095, 2014.","DOI":"10.1111\/dom.12322"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/21\/60_7134-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T23:20:45Z","timestamp":1636154445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/21\/60_7134-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":36,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7134-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"article-number":"7134-21"}}